Introduction A pharmacopoeia is a legally binding reference work containing quality standards for medicines, excipients, and other pharmaceutical substances. It serves as the foundation for ensuring that drugs available to the public are safe, effective, and of consistent quality. In Indonesia, the national pharmacopoeia, known as Farmakope Indonesia (FI), has undergone several revisions to meet evolving scientific and regulatory needs. The third edition, Buku Farmakope Edisi 3 (often abbreviated FI III), represents a critical milestone in the country’s journey toward pharmaceutical self-reliance and harmonization with international standards. This essay explores the background, content, regulatory role, and lasting impact of FI III. Historical Context and Development The first edition of Farmakope Indonesia was published in 1972, following Indonesia’s independence and the need to move away from colonial-era references such as the Nederlandsch-Indische Pharmacopee . The second edition (FI II) appeared in 1978, introducing improvements but still largely based on older monographs. By the late 1980s, rapid advances in pharmaceutical science, the emergence of new drug molecules, and the globalization of drug supply chains demanded a more comprehensive and updated standard.